This site is intended for healthcare professionals

FDA extends PDUFA date for Myfembree to manage moderate to severe pain associated with endometriosis . Myovant Sciences + Pfizer

Read time: 1 mins
Published:7th May 2022

Myovant Sciences and Pfizer Inc. announced that the FDA has extended the review period for the supplemental New Drug Application (sNDA) for Myfembree (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis.


The FDA requires extended time to review additional information the Agency requested from the companies regarding bone mineral density. The extended Prescription Drug User Fee Act (PDUFA) goal date is 6 August 2022.

Condition: Pain; Endometriosis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.